manufacturing process

Pharma

Bluebird tanks with FDA delay of LentiGlobin in sickle cell

The FDA is raising questions about the manufacturing of Bluebird's gene therapy for sickle cell, pushing that filing back a year to late 2022.
Arlene Weintraub Nov 5, 2020 10:58am

Aurobindo chalks up new FDA manufacturing concerns

Oct 8, 2019 9:16am

FDA cites solvent recycler as player in valsartan mess

Aug 15, 2019 8:09am

Botox rival, FDA inspections, Daiichi and more—FiercePharmaAsia

Aug 9, 2019 10:50am

Merck KGaA, Jenner hook up to improve vaccine manufacturing

Apr 16, 2018 12:10pm

MilliporeSigma, Baylor team up for neglected disease vax work

Aug 8, 2017 4:05pm